The Cardiovascular Pharmaceutical Cornucopia: A Conundrum of Riches
- PMID: 35331407
- DOI: 10.1016/j.jacc.2022.01.028
The Cardiovascular Pharmaceutical Cornucopia: A Conundrum of Riches
Keywords: empagliflozin; heart failure with preserved ejection fraction; hyperkalemia; mineralocorticoid receptor antagonists; treatment effect.
Conflict of interest statement
Funding Support and Author Disclosures Dr Konstam has served on the data monitoring committee for the EMPEROR-Preserved trial for Boehringer Ingelheim and continues to consult for the company in a similar role.
Comment on
-
Mineralocorticoid Receptor Antagonists and Empagliflozin in Patients With Heart Failure and Preserved Ejection Fraction.J Am Coll Cardiol. 2022 Mar 29;79(12):1129-1137. doi: 10.1016/j.jacc.2022.01.029. J Am Coll Cardiol. 2022. PMID: 35331406 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
